Data Sheet (Cat.No.T39954)

TargetMol
YOUR TARGET MOLECULES

AU-15330

Chemical Properties



CAS No. : 2380274-50-8

Formula: C39H49N9O5S

Molecular Weight: 755.93

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	AU-15330 is a protein hydrolysis-targeted chimeric (PROTAC) degrader of the SWI/SNF ATPase subunits SMARCA2 and SMARCA4.AU-15330 potently inhibits tumor growth in a prostate cancer xenograft model and acts synergistically with the AR antagonist enzalutamide.AU-15330 shows partial therapeutic efficacy and non-toxicity with the AR antagonist enzalutamide in a desmoplasia-resistant prostate cancer (CRPC) model. AU-15330 showed partial therapeutic efficacy in a denervation-resistant prostate cancer (CRPC) model and AU-15330 was characterized by non-toxicity.
Targets(IC50)	Epigenetic Reader Domain,PROTACs
In vivo	AU-15330 (10 and 30 mg/kg; i.v.; 5 days per week for 3 weeks) shows no evident toxicity in immuno-competent mice.[1] AU-15330 (60 mg/kg with or without 10 mg/kg enzalutamide; i.v.; 3 days per week; p.o.; 5 days per week for 5 weeks) leads to potent inhibition of tumor growth, triggering disease regression in more than 20% of animals. The combinatorial regimen induced the most potent anti-tumor effect, with regression in all animals.[1] AU-15330 (60 mg/kg with or without 10 mg/kg enzalutamide; i.v.; 3 days per week; p.o.; 5 days per week for 5 weeks) strongly inhibits the growth of C4-2B cell line-derived CRPC xenografts in intact mice as a single agent and synergized with enzalutamide.[1] AU-15330 (60 mg/kg with or without 10 mg/kg enzalutamide; i.v.; 3 days per week; p.o.; 5 days per week for 5 weeks) combines with enzalutamide induces significant tumor growth inhibition, causing regression in more than 30% of animals in the middle of CRPC variant of the MDA-PCa-146-12 PDX by tumor implantation into castrated

Solubility Information

Solubility	DMSO: 126.0 mg/mL (166.7 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.3229 mL	6.6144 mL	13.2287 mL
5 mM	0.2646 mL	1.3229 mL	2.6457 mL
10 mM	0.1323 mL	0.6614 mL	1.3229 mL
50 mM	0.0265 mL	0.1323 mL	0.2646 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Xiao L, et al. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature. 2022;601(7893):434-439.
Xiao L, et al. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature. 2022;601(7893):434-439.